For many people living with chronic pain, kratom has become a controversial but increasingly visible part of the self-management landscape, sitting in a grey area between traditional herbal remedy and unapproved drug. In the United States, regulators such as the Food and Drug Administration (FDA) continue to warn that kratom is not lawfully marketed as a drug, dietary supplement or food additive, even as patients experiment with new formulations that promise to make the bitter leaf more palatable.
Against that backdrop, Pain News Network columnist Crystal Lindell set out to answer a simple but practical question: can kratom edibles like taffy, chocolate, soft gels and even a seltzer-style drink make daily dosing easier without sacrificing effect? Her review, based on four years of using loose kratom powder to manage debilitating rib pain from intercostal neuralgia, offers a ground-level snapshot of how this emerging product category stacks up against the old standby of bulk powder.
Kratom, derived from the leaves of the Southeast Asian tree Mitragyna speciosa, has a long history of traditional use by laborers in countries such as Thailand and Malaysia, who chewed fresh leaves or brewed them into tea to fight fatigue and pain. A fact sheet from the U.S. Drug Enforcement Administration notes that the plant’s alkaloids, including mitragynine and 7-hydroxymitragynine, can produce stimulant effects at low doses and opioid-like effects at higher doses, and warns that consumption can lead to dependence in some users; the agency also stresses that kratom has no approved medical use in the United States. For patients like Lindell, however, the immediate concern is not abstract pharmacology but whether a given product reliably eases pain, how fast it works, how it tastes, and what it costs.
Lindell’s baseline is loose powder purchased in bulk from a local smoke shop, at roughly $150 per kilogram, which she calculates to about 70 cents per 5-gram dose when bought in kilo quantities. She typically uses that dose every three to five hours while awake, depending on pain levels, and administers it via the so-called “toss and wash” method: placing a spoonful of powder under the tongue and chasing it with a non-carbonated drink. The experience is far from pleasant — she likens the taste to “dry dirt” — but the trade-off is speed and affordability, with relief arriving in under three minutes by her account.
Crucially, Lindell stresses that her review was not sponsored, although companies did send samples for evaluation after Pain News Network reached out; that detail matters in a marketplace where kratom is largely unregulated at the federal level and products can vary widely in quality. The FDA has documented instances of kratom products contaminated with pathogens such as salmonella and has issued import alerts and warning letters over adulterated or misbranded items, underscoring why independent, experience-based reviews can be valuable for consumers navigating the space.
The standout product in Lindell’s testing was Raw Kratom Taffy sold by CBD Kratom, which she rated five out of five stars. The individually wrapped taffies are available in multiple strains, including red, white, green and gold Maeng Da, giving consumers an unusual degree of control over the type of kratom they are ingesting. For Lindell, who strongly prefers red Maeng Da and dislikes white strains, that level of transparency and choice was a major plus, mirroring long-standing user practices of selecting strains based on perceived differences in pain relief, sedation or stimulation.
Each taffy is labeled as containing 20 milligrams of kratom, and Lindell reports that a third of a piece was sufficient to bring significant relief during a particularly bad evening, suggesting the taffy is potent enough to be divided into multiple doses. Onset time was under 30 minutes in her experience, a slower curve than sublingual powder but still within the range many patients associate with conventional oral pain medications. The flavor, created with fruit juices, did not read as candy in a confectionery sense but crucially did not trigger the aversion that plain powder does for many first-time users.
The drawbacks were physical and financial. The taffy was so tough that Lindell worried about damaging her teeth, an issue that may be amenable to formulation tweaks but is non-trivial for patients with dental problems or jaw pain. Price was the other sticking point: at about six dollars per piece, the cost per dose is far higher than bulk powder, making it difficult to justify as a daily workhorse product even if its taste and strain labeling are superior. For now, she sees it as an occasional option rather than a full replacement.
PurKratom’s soft gels earned four out of five stars and might have taken the top spot if not for their price. Sold in bottles of 20, each soft gel contains 33 milligrams of kratom extract, marketed as a high-concentration organic formulation. Lindell found them dramatically easier to swallow than either powder or candy, likening the experience to taking familiar liquid-filled pain relievers; one capsule at a time delivered relief within about 30 minutes without making her feel foggy or producing an unpleasant head rush.
Ease of use is no small thing for patients who struggle with gag reflex, taste sensitivity or gastrointestinal irritation from traditional preparations. Yet the economics again pose a barrier: at $79.99 for 20 capsules, each soft gel effectively costs about four dollars, many times more per dose than the loose powder Lindell buys locally. Unlike tablets, soft gels cannot be split to adjust the dose or stretch the bottle, making the initial investment steep, particularly for people just experimenting to see whether kratom will help their symptoms.
Lindell notes that she would like to see the soft gels differentiated by strain, as with the taffy, to give users more insight into how specific varieties affect them. That desire for better labeling dovetails with broader calls from advocates for standardized testing and disclosure in the kratom industry, even as agencies such as the FDA and organizations like the National Institute on Drug Abuse emphasize that much remains unknown about the botanical’s safety profile, its potential for dependence, and its interactions with other substances.
One of the more novel products Lindell tried was a kratom seltzer from Korthal’s Collection, labeled as containing 75 milligrams of full-spectrum mitragynine per 16-ounce can and marketed for focus, mood elevation and energy. At $35 plus shipping for a four-pack, the pricing again places it firmly in the “treat” category for many budgets, more akin to a specialty functional beverage than a commodity supplement. Lindell describes the taste as reminiscent of a strong tea or bitter alcoholic drink, not exactly refreshing but not intolerable when well chilled.
In terms of pharmacological effect, a full can proved potent; Lindell herself consumed only about a third and felt significant impact within 20 minutes, while her fiancé, who lives with chronic pain as well, drank an entire can and reported benefits for both pain and mood. Interestingly, the subjective experience diverged from the product’s energy-focused positioning: rather than feeling stimulated, Lindell found the effect more relaxing and subduing, which may reflect individual variation in response or the influence of dose. That ambiguity mirrors the broader scientific picture, where researchers have documented both stimulant-like and opioid-like actions depending on dose, strain and user profile, and where systematic clinical trials remain limited.
Still, the seltzer’s lingering aftertaste and premium pricing make it hard for Lindell to imagine stocking it regularly at home, though she can envision grabbing a single can from a local shop occasionally when buying powder. That distinction between niche indulgence and daily staple recurs throughout her review, highlighting the tension between innovation and accessibility in a largely out-of-pocket market.
Korthal’s Collection also supplied kratom-infused milk and dark chocolate bars, which Lindell approached with high expectations given her fondness for both chocolate and kratom. Each 1.3-ounce bar, sold for around $20, is divided into eight squares, with packaging that lists 25 milligrams of mitragynine per serving. The company suggests the bars may offer energy, pain relief and mood enhancement, positioning them similarly to other so-called functional chocolates that blend cocoa with botanicals or cannabinoids.
Flavor-wise, the bars occupy a middle ground: they do not taste like conventional chocolate, but they also avoid the raw, vegetal bitterness of straight kratom powder. Lindell found them chocolaty enough that even people unaccustomed to kratom could manage a square, especially older relatives who might be wary of powders or tinctures. One square was sufficient to produce noticeable effects within about half an hour, easing physical pain but also producing a somewhat disconnected head buzz that she did not find entirely pleasant.
As with the taffy and seltzer, aftertaste and cost were the primary negatives. Lindell often followed a square with a chaser to clear the lingering flavor, and at $20 per bar, the price compares more to premium CBD confections than to commodity candy. She also raises a safety concern that extends beyond any one brand: the need for child-resistant packaging and clear labeling on kratom edibles, given their candy-like appearance. Public health agencies have documented an increase in calls to U.S. poison centers involving kratom exposures over the past decade, including accidental ingestions, and regulators warn that unapproved products can pose particular risks to children and adolescents.
Across all four products, Lindell returns repeatedly to two core benchmarks: speed of onset and cost per dose. By those measures, her bulk powder remains difficult to beat, providing relief in under three minutes at a fraction of the per-dose price of taffy, chocolates, soft gels or seltzer. For someone managing constant, severe pain, the ability to cut minutes off the wait for relief can be more than a mere convenience; it can shape whether a formulation is realistic for day-to-day use. At the same time, she acknowledges that not everyone needs or wants rapid-onset relief, and for many people the 20- to 30-minute window offered by edibles will feel familiar from over-the-counter pain medications.
Her bottom line is nuanced rather than dismissive. Lindell continues to rely primarily on the “spoonful of soil-flavored powder” that first made her daily life manageable, but she sees a clear role for kratom edibles and refined capsules as alternatives for people who cannot tolerate the taste or texture of powder. If prices on products like PurKratom’s soft gels were to drop, she says she would likely incorporate them into her own routine more regularly and plans to purchase them for relatives who may benefit from kratom but are put off by traditional delivery methods. Her fiancé’s positive experience with the seltzer suggests that, for some users, drinkable formulations could also offer a welcome variation.
More broadly, the proliferation of kratom candies, beverages and encapsulated extracts signals an industry maturing beyond anonymous bags of ground leaf, even as regulatory and scientific questions remain unsettled. The FDA has reiterated that no kratom product is approved to diagnose, treat, cure or prevent any disease, and expert bodies convened by the World Health Organization’s Expert Committee on Drug Dependence have concluded that evidence is not yet sufficient to recommend international scheduling but have called for continued monitoring of mitragynine and related compounds. For patients and clinicians, that means balancing anecdotal benefits against documented risks, in consultation with health professionals and with careful attention to product quality, dosing and potential interactions.
In the meantime, Lindell’s experience illustrates both the promise and limitations of kratom edibles: they can soften the harshness of the plant’s taste and offer familiar formats like chocolates or gels, but they rarely match the immediacy or economy of simple powder. For a subset of pain patients, that trade-off will be worth it; for others, the old ritual of measuring a spoonful of bitter green powder and chasing it with a drink will remain the most practical way to harness a controversial leaf that, for all the debate swirling around it, still sits firmly outside the bounds of conventional medicine.